Morales, Maria L. published the artcileTriclabendazole treatment failure for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru, Product Details of C12H9N3O5S, the main research area is Fasciola hepatica triclabendazole antimicrobial chronic fascioliasis; Cusco; Fasciola hepatica; Peru; antimicrobial resistance; drug resistance; efficacy; fascioliasis; infection; liver fluke; parasites; preschool children; school-age children; treatment failure; trematode; triclabendazole.
We conducted a retrospective cohort study of children who had chronic fascioliasis in the highlands of Peru to determine triclabendazole treatment efficacy. Children passing Fasciola eggs in stool were offered directly observed triclabendazole treatment (>1 doses of 10 mg/kg). Parasitol. cure was evaluated by using microscopy of stool 1-4 mo after each treatment. A total of 146 children who had chronic fascioliasis participated in the study; 53% were female, and the mean ± SD age was 10.4 ± 3.1 years. After the first treatment, 55% of the children achieved parasitol. cure. Cure rates decreased after the second (38%), third (30%), and fourth (23%) treatments; 17 children (11.6%) did not achieve cure after 4 treatments. Higher baseline egg counts and lower socioeconomic status were associated with triclabendazole treatment failure. Decreased triclabendazole efficacy in disease-endemic communities threatens control efforts. Further research on triclabendazole resistance and new drugs to overcome it are urgently needed.
Emerging Infectious Diseases published new progress about Bioavailability. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Product Details of C12H9N3O5S.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics